Navigation Links
New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
Date:10/24/2007

k at least one dose of treatment, found that treatment-emergent adverse events were reported in approximately 63% of AMBIEN CR-treated patients compared to 50% of patients treated with placebo. Serious adverse events were reported in approximately 3% of study patients taking AMBIEN CR compared to approximately 2% of patients treated with placebo. These adverse events were not considered by the investigator to be related to the study treatment.

About Insomnia

Insomnia can be a serious medical condition characterized by difficulty falling asleep, waking up often during the night and having trouble going back to sleep, waking up too early in the morning and feeling tired upon waking. More than 30 million Americans are affected by chronic insomnia each year.

Patients with chronic insomnia report higher rates of absenteeism and demonstrate poor work efficiency compared to normal sleepers. Chronic and occasional insomniacs were both more likely to doze off during daytime activities or when bored, and to take naps than individuals who do not experience insomnia. Insomnia can lead to stress and reduced productivity, and thus may be costly to the workplace.

About AMBIEN CR

AMBIEN CR is the first and only dual-layer, extended-release prescription sleep medication indicated to help induce and maintain sleep with no significant decrease in next-day performance. AMBIEN CR is delivered in two stages. The first layer dissolves quickly to induce sleep. The second layer is released more gradually into the body to help provide more continuous sleep.

Important Safety Information

AMBIEN CR is a treatment option you and your healthcare provider can consider along with lifestyle changes and can be taken for as long as your provider recommends. Until you know how AMBIEN CR will affect you, you shouldn't drive or operate machinery. Be sure you're able to devote 7 to 8 hours to sleep before being active again. Sleepwalking, and eating or driving whi
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
4. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
10. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
11. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Stryker brand ambassadors Fred Funk ... 3M Championship Champions Tour event near Minneapolis, MN ... Blaine . Stryker is the official joint replacement products company ... Friday, August 1 st through Sunday, August 3 rd , ... on-site joint health destination located in the Pioneer Press Expo tent ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July 30, 2014 ... ARNA ) announced today that an article based on post-hoc ... entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise ... published in the online issue of Obesity , the ... of these analyses was to identify whether there is an ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Laboratories, Inc. (OTCBB: UGNE), a leader in ... therapeutics, today announced the Company,s Vice President of ... presenting at IBC,s 4th Annual AsiaTIDES Oligonucleotide and ... Hotel in Tokyo, Japan. The TIDES ...
... DIEGO, Feb. 27, 2012 Optimer Pharmaceuticals, Inc. (NASDAQ: ... and fiscal year 2011 financial results and provide a ... the NASDAQ Global Market closes on March 7th.  The ... at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). ...
Cached Medicine Technology:Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference 2Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference 3Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results 2
(Date:7/30/2014)... 2014 Conducting Advanced Root Cause ... Skills and Innovative Techniques to Improve the Quality ... FDAnews**, Sept. 17-18, 2014 – Raleigh, NC, ... reason for 483 observations since 1997. , The ... successful CAPA program has never been more important. ...
(Date:7/30/2014)... 30, 2014 Good Neighbor Community ... an upcoming episode of Innovations with Ed Begley ... Dates and show times TBA. , In this ... Community Services’ vision to redefine the traditional approach ... dynamic services. Through passion, innovation, determination, excellence, and ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 SF Cable, ... at the lowest prices on the internet with guaranteed ... in two lengths and two colors. These lightning cords ... , The high quality SF Cable Lightning ... with digital signal delivering faster charging and syncing. Compatible ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery ... Carmel office on July 30th. After months of planning, ... to the state-of-the-art suite, located only steps away from ... allow for one-on-one patient comfort, shorter wait times, and ... Dr. Hamilton’s new office-suite will continue to provide the ...
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people with diverticulitis ... week in the peer-reviewed journal Quality of Life Research , a UCLA team led by Dr. Brennan Spiegel interviewed patients in ...
Breaking Medicine News(10 mins):Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3
... imaging technique developed at the University of Illinois ... neurological problems, such as// Chiari malformations, hydrocephalus and ... through a $1.4 million National Institutes of Health ... which draws on bioengineering, radiology and neurosurgery, will ...
... cells, seem to be obstinate, as scientists have discovered, ... a result, they are extremely// difficult to annihilate. In ... stem cells, warn researchers from the University of California, ... this tendency of stem cells that get radiation resistant ...
... stay fit, old people especially those who are 70 and ... indulge// in brain exercises, to enhance their cognitive abilities to ... ,Previous insights have indicated the benefits of engaging ... led by Sherry Willis, a human-development professor at Penn State ...
... of brain fever has killed 35 children in three months ... ,After Japanese encephalitis and viral encephalitis killed at least ... mysterious but fatal virus is prowling the region claiming children ... large so we are actually at a loss as to ...
... from olive oil, glycerine and egg yolk would ... surgery.// ,The journal of Catheterization and Cardiovascular ... led by Michael Savage, M.D., director, Cardiac Catheterization ... ,The mixture is not swallowed, Dr. Savage explains. ...
... Pradesh legislative assembly will undergo tests to screen for AIDS.// ... R. Suresh Reddy, Health Minister K. Rosaiah and leaders of ... camp held for legislators in the assembly premises. , ... should undergo the tests to set an example for others. ...
Cached Medicine News:Health News:New MRI Technique Measures Intracranial Pressure in Brain Disorder 2Health News:Olive Oil Emulsions Prevent Cardiac Bypass Surgery 2
... flow while minimizing the pain ... the safety-engineered BD Microtainer Genie ... Lancet offers a full range ... capillary blood collection and protects ...
... Maximize blood flow and minimize pain ... the safety-engineered BD Microtainer Quikheel Lancet. ... surgical blade providing a precise and ... retracts into its casing, helping to ...
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading....
The Minilyser offers a combination of three well proven instruments for fully automated processing of microplates. The Minilyser is the optimal fully automated ELISA and EIA equipment for laboratorie...
Medicine Products: